Nanopharmaceuticals (Part 2): Products in the pipeline

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 1245-1257

  Weissig, Volkmar ^a   Guzman Villanueva, Diana ^a  

^a MIDWESTERN UNIVERSITY   (United States)

Author keywords

Nano based properties; Nanodrugs; Nanomedicine; Nanoparticles; Nanopharmaceuticals; Surface plasmon resonance

Indexed keywords

ANTINEOPLASTIC AGENT; CD34 SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE CONJUGATE; FERUMOXYTOL; GADOLINIUM PENTETATE MEGLUMINE; GOLD NANOPARTICLE; HAFNIUM NANOPARTICLE; IRON NANOPARTICLE; NANOMATERIAL; NANOSHELL; NANOTUBE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; SILICA NANOPARTICLE; SUPERPARAMAGNETIC IRON OXIDE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BIOPSY; CLINICAL TRIAL (TOPIC); DRUG FORMULATION; DRUG SYNTHESIS; HUMAN; MAGNETIC BIOPSY; MAGNETIC THERMOABLATION; MAGNETISM; NANOENGINEERING; NANOPHARMACEUTICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAMAGNETISM; PARTICLE SIZE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; REVIEW; TUMOR ABLATION; MEDICINAL CHEMISTRY; NANOMEDICINE;

CHEMISTRY, PHARMACEUTICAL; NANOMEDICINE;

EID: 84922900581     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S65526     Document Type: Review

References (56)

1. Weissig V, Pettinger TK, Murdock N. Nanopharmaceuticals (part I): products on the market. Int J Nanomedicine. 2014;9:4357–4373.
2. Rivera Gil P, Huhn D, del Mercato LL, Sasse D, Parak WJ. Nanophar-macy: inorganic nanoscale devices as vectors and active compounds. Pharmacol Res. 2010;62(2):115–125.
3. International Council of Chemical Associations [homepage on the Internet]. Available from: http://www.icca-chem.org/. Accessed September 18, 2014.
4. National Institute for Occupational Safety and Health [homepage on the Internet]. Available from: http://www.cdc.gov/niosh/docs/2009-125. Accessed September 18, 2014.
5. Stanford University Environmental Health [homepage on the Internet]. Available from: http://www.stanford.edu/dept/EHS/prod/. Accessed September 18, 2014.
6. Nano.gov [homepage on the Internet] National Nanotechnology Initiative. Available from: http://www.nano.gov/nanotech-101/special. Accessed September 18, 2014.
7. Nano.gov [homepage on the Internet] Available from: http://www.nano. gov/nanotechnology-initiative/nano-achievements/nanotechnology-initiatives/nano-achievements. Accessed May 6, 2014.
8. Duncan R, Ringsdorf H, Satchi-Fainaro R. Polymer therapeutics-polymers as drugs, drug and protein conjugates and gene delivery systems: past, present and future opportunities. J Drug Target. 2006;14(6): 337–341.
9. Staudinger H. Viscosity investigations for the examination of the constitution of natuatrl products of high molecualr weight and of rubber and cellulose. Trans Faraday Soc. 1933;29:18–32.
10. Batz HG, Franzmann G, Ringsdorf H. Model reactions for synthesis of pharmacologically active polymers by way of monomeric and polymeric reactive esters. Angew Chem Int Ed Engl. 1972;11(12):1103–1104.
11. Ringsdorf H. Macromolecular compounds as potential protective agents against ionizing rays. Strahlentherapie. 1967;132:627–635.
12. Kopecek J. Soluble biomedical polymers. Polimery w Medycynie. 1977; 7:191–221.
13. Kopecek J. Controlled biodegradability of polymers-a key to drug delivery systems. Biomaterials. 1984;5:19–25.
14. Duncan R. Biological effects of soluble synthetic polymers as drug carriers. Crit Rev Ther Drug Carrier Syst. 1985;1(4):281–310.
15. Kopecek J, Rejmanova P, Duncan R, Lloyd JB. Controlled release of drug model from N-(2-hydroxypropyl)-methacrylamide copolymers. Ann N Y Acad Sci. 1985;446:93–104.
16. PubMed.gov [homepage on the Internet] Clinical Trails. Available from http://clinicaltrials.gov/. Accessed May 5, 2014.
17. US National Library of Medicine National Institutes of Health [homepage on the Internet]. Available from http://www.ncbi.nlm.nih.gov/pubmed/. Accessed September 8, 2014.
18. Zhu D, Liu F, Ma L, Liu D, Wang Z. Nanoparticle-based systems for t1-weighted magnetic resonance imaging contrast agents. Int J Mol Sci. 2013;14(5):10591–10607.
19. Mandarano G, Lodhia J, Eu P, Ferris NJ, Davidson R, Cowell SF. Development and use of iron oxide nanoparticles (Part 2): the application of iron oxide contrast agents in MRI. Biomed Imaging Interv J. 2010;6:1–14.
20. Corot C, Robert P, Idee JM, Port M. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev. 2006; 58(14):1471–1504.
21. Bourrinet P, Bengele HH, Bonnemain B, et al. Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall superpara-magnetic iron oxide magnetic resonance contrast agent. Invest Radiol. 2006;41(3):313–324.
22. Weinstein JS, Varallyay CG, Dosa E, et al. Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system infammatory pathologies, a review. J Cereb Blood Flow Metab. 2010;30(1):15–35.
23. Wang YX. Superparamagnetic iron oxide based MRI contrast agents: current status of clinical application. Quant Imaging Med Surg. 2011; 1(1):35–40.
24. Schroeter M, Franke C, Stoll G, Hoehn M. Dynamic changes of magnetic resonance imaging abnormalities in relation to inflammation and glial responses after photothrombotic cerebral infarction in the rat brain. Acta Neuropathol. 2001;101(2):114–22.
25. Bullivant JP, Zhao S, Willenberg BJ, Kozissnik B, Batich CD, Dobson J. Materials characterization of Feraheme/ferumoxytol and preliminary evaluation of its potential for magnetic fluid hyperthermia. Int J Mol Sci. 2013;14(9):17501–17510.
26. Provenzano R, Schiller B, Rao M, Coyne D, Brenner L, Pereira BJ. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol. 2009;4(2):386–393.
27. Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengele HH, Josephson L. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology. 1990;175(2):489–493.
28. Paul KG, Frigo TB, Groman JY, Groman EV. Synthesis of ultrasmall superparamagnetic iron oxides using reduced polysaccharides. Biocon-jug Chem. 2004;15(2):394–401.
29. Jahn MR, Andreasen HB, Futterer S, et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm. 2011;78(3):480–491.
30. Balakrishnan VS, Rao M, Kausz AT, et al. Physicochemical properties of ferumoxytol, a new intravenous iron preparation. Eur J Clin Invest. 2009;39(6):489–496.
31. Spinowitz BS, Schwenk MH, Jacobs PM, et al. The safety and effcacy of ferumoxytol therapy in anemic chronic kidney disease patients. Kidney Int. 2005;68(4):1801–1807.
32. Hudgins PA, Anzai Y, Morris MR, Lucas MA. Ferumoxtran-10, a superparamagnetic iron oxide as a magnetic resonance enhancement agent for imaging lymph nodes: a phase 2 dose study. AJNR Am J Neuroradiol. 2002;23(4):649–656.
33. Muller K, Skepper JN, Posfai M, et al. Effect of ultrasmall super-paramagnetic iron oxide nanoparticles (Ferumoxtran-10) on human monocyte-macrophages in vitro. Biomaterials. 2007;28: 1629–1642.
34. Groman EV, Josephson L, Lewis JM, inventors; Advanced Magnetics, Incorporated, assignee. Magnetic resonance imaging. United States patent US4827945 A. May 9, 1989.
35. Molday RS, Molday LL. Separation of cells labeled with immunospe-cifc iron dextran microspheres using high gradient magnetic chroma-tography. FEBS Lett. 1984;170(2):232–238.
36. Jung CW, Jacobs P. Physical and chemical properties of superpara-magnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging. 1995;13(5):661–674.
37. Jung C W. Surface properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging. 1995;13(5):675–691.
38. Jaetao JE, Butler KS, Adolphi NL, et al. Enhanced leukemia cell detection using a novel magnetic needle and nanoparticles. Cancer Res. 2009;69(21):8310–8316.
39. Adolphi NL, Huber DL, Bryant HC, et al. Characterization of single-core magnetite nanoparticles for magnetic imaging by SQUID relax-ometry. Phys Med Biol. 2010;55(19):5985–6003.
40. Adolphi NL, Huber DL, Jaetao JE, et al. Characterization of magnetite nanoparticles for SQUID-relaxometry and magnetic needle biopsy. J Magn Magn Mater. 2009;321:1459–1464.
41. Bradbury MS, Phillips E, Montero PH, et al. Clinically-translated silica nanoparticles as dual-modality cancer-targeted probes for image-guided surgery and interventions. Integr Biol (Camb). 2013;5(1):74–86.
42. Petryayeva E, Krull UJ. Localized surface plasmon resonance: nano-structures, bioassays and biosensing – a review. Anal Chim Acta. 2011; 706:8–24.
43. Cobley CM, Au L, Chen J, Xia Y. Targeting gold nanocages to cancer cells for photothermal destruction and drug delivery. Expert Opin Drug Deliv. 2010;7(5):577–587.
44. Khlebtsov N, Bogatyrev V, Dykman L, et al. Analytical and theranostic applications of gold nanoparticles and multifunctional nanocomposites. Theranostics. 2013;3:167–180.
45. Sikdar D, Rukhlenko ID, Cheng W, Premaratne M. Effect of number density on optimal design of gold nanoshells for plasmonic photothermal therapy. Biomed Opt Express. 2013;4(1):15–31.
46. Kharlamov AN. Plasmonic photothermal therapy for atheroregression below Glagov threshold. Future Cardiol. 2013;9(3):405–425.
47. Kharlamov AN, Tyurnina AE, Veselova VS, Novoselova OS, Filatova AS. Plasmonics for treatment of atherosclerosis: Results of NANOM-FIM trial. J Nanomed Nanotechnol. 2013;4:160.
48. Kharlamov AN, Gabinsky JL. Plasmonic photothermic and stem cell therapy of atherosclerotic plaque as a novel nanotool for angioplasty and artery remodeling. Rejuvenation Res. 2012;15:222–230.
49. Stoeber W, Fink A, Bohn E. Controlled growth of monodisperse silica spheres in the micron size range. J Colloid Interface Sci. 1968;26:62–69.
50. Lee KY, Lee YW, Kwon K, Heo J, Kim J, Han S W. One-step fabrication of gold nanoparticles-silica composites with enhanced catalytic activity. Chem Phys Lett. 2008;453:77–81.
51. Bao C, Conde J, Polo E, et al. A promising road with challenges: where are gold nanoparticles in translational research? Nanomedicine (London). 2014;9(15):2353–2370.
52. Conde J, Dias JT, Moros M, Baptista PV, de la Fuente JM. Revisiting 30 years of biofunctionalization and surface chemistry of inorganic nanoparticles for nanomedicine. Front Chem. 2014;2:1–27.
53. Marill J, Anesary NM, Zhang P, et al. Hafnium oxide nanoparticles: toward an in vitro predictive biological effect? Radiat Oncol. 2014;9:150.
54. Pottier A, Borghi E, Levy L. New use of metals as nanosized radioen-hancers. Anticancer Res. 2014;34:443–453.
55. Levy L, Pottier A, Rouet A, Marill J, Devaux C, Germain M, inventors; Nanobiotix, assignee. Inorganic nanoparticles of high density to destroy cells in vivo. United States patent US8845507B2. June 4, 2009.
56. Maggiorella L, Barouch G, Devaux C, et al. Nanoscale radiotherapy with hafnium oxide nanoparticles. Future Oncol. 2012;8(9):1167–1181.